Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

14.10 EUR

-2.08 %

5,599 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-2.08 %
+0.36 %
+10.59 %
+36.23 %
+78.48 %
+102.01 %
+236.52 %
+150.82 %
-97.67 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
101.71M EUR
Turnover
130.92K EUR
P/E (adj.) (25e)
24.96
EV/EBIT (adj.) (25e)
24.28
P/B (25e)
12.9
EV/S (25e)
6.58
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.50 EUR
Updated
2025-08-18
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2025-08-18

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I don’t really understand this precision that investors demand from reporting anymore… the company is starting to have an annual sales of about 50 devices plus continuous invoicing, and they want real-time visibility into individual device sales. No company reports its sales at this...
13 hours ago
by Puutaheinää
24
This is the case for all companies. Information on the growth/shrinkage of sales and order backlog is handled quarterly in interim/business reviews, with guidance, and if necessary, with earnings warnings, negative or positive. Where does this requirement come from that Nexstim should...
13 hours ago
by Puutaheinää
14
Just earlier, the CEO stated very clearly that “We continue to report the hardware volumes delivered to all our customers (thus including hardware delivered to Brainlab) four times a year, i.e., in the Q1 and Q3 business updates and the H1 and H2 earnings reports.”. So the delivery...
7 hours ago
by SentinVenyttäjä
13
In these companies, you always have to wait for the earnings report for the truth to be revealed. Unless there’s a warning before that. It would be nice to have real-time information on how things are going. Now, if you sell or buy, you have to speculate on what the result will be...
12 hours ago
by QRB Strong buy
13
The company is at the root of such a big healthcare megatrend (e.g., treatment of depression) and the scalable market is global, so there are no limits – current trade reporting is quite okay for now, at least for some investor-savers. If this were a US company, then… Well, next ...
9 hours ago
by Prototyping
10
This is precisely my point, there shouldn’t be announcements when the size of the deals is something like 1-2% of turnover. When this business was being ramped up, it was a different matter. My regards to your fellow small investor: focus on larger entities, and it’s not the company...
13 hours ago
by Puutaheinää
8
Now Nexstim instructs as follows: “Outlook for 2025 The company estimates that revenue will grow and operating profit will improve.” No one can really call this very precise guidance. That’s why people are calculating how many devices will be sold compared to 2024. And that raises...
13 hours ago
by enska
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.